HRA is putting feet on the ground in China as it looks to establish itself in the world second-largest consumer health market. 

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

FDA adds 53 entries to the list of standards it will recognize for device pre-market submissions, and grants de novo approval for two device types. Civil money penalty amounts increase on inflation adjustment. The Center for Biologics Evaluation and Research searches for a review branch chief. More regulatory news.

Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.